Background-The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in major depression. Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy.
Introduction
A single subanesthetic dose of ketamine has been shown to reduce depressive symptoms within hours in major depression (aan het Berman et al., 2000; Messer et al., 2010; Murrough et al., 2013; Valentine et al., 2011; Zarate et al., 2006) and bipolar disorder (Diazgranados et al., 2010; Zarate et al., 2012) patients. This effect is sustained for approximately 1-2 weeks . While results are encouraging, most patients experience transient dissociation and psychotomimetic side effects and hemodynamic changes (e.g., increases in blood pressure) that limit its clinical use (Green and Johnson, 1990 ).
Other noncompetitive (Zarate et al., 2013) and more specific NMDA receptor antagonists Preskorn et al., 2008 ) have antidepressant efficacy in major depression and are relatively devoid of psychotomimetic and dissociative side effects. The effects of these other antagonists, however, are not as robust as ketamine, which may reflect their decreased binding/affinity for the NMDA receptor complex (Aan Het Rot et al., 2012) . Thus, it is unclear if the psychotomimetic sequelae, dissociative experiences, and/or hyperdynamic vital sign changes associated with a sub-anesthetic dose of ketamine are necessary to achieve antidepressant effects. Therefore, the objective of this analysis was to determine whether increased sympathomimetic and hypoglutamatergic effects were related to ketamine's antidepressant efficacy. We hypothesized that increased sympathomimetic and hypoglutamatergic (psychotomimetic and dissociative) effects would correlate with changes in depression on ketamine.
Methods
We analyzed data from 108 treatment-resistant depression patients (MDD=74; BD=34) in a current major depressive episode without psychotic features, diagnosed according to the Structured Clinical Interview for Axis I DSM-IV Disorders-Patient Version (First et al., 2002 ) (see Diazgranados et al., 2010; Ibrahim et al., 2012; Zarate et al., 2012 Zarate et al., , 2006 for study details). For two studies, ketamine was administered double-blind (Diazgranados et al., 2010; Zarate et al., 2012 Zarate et al., , 2006 while in the third study, ketamine was delivered open-label (MDD, n=42) . The inpatient studies were conducted at the National Institutes of Mental Health Clinical Research Center in Bethesda, MD, USA. All participants provided written informed consent as approved by the NIH Combined Neuroscience Institutional Review Board. Subjects had at least a moderate severity episode of major depression, as measured as ≥18 on the 21-item Hamilton Depression Rating Scale (HDRS) or ≥20 on the Montgomery-Asberg Depression Rating Scale (MADRS) for at least four weeks at screening and the start of each infusion, and had a history of at least one failed antidepressant drug trial in a current or past depressive episode. Exclusion criteria included a DSM-IV diagnosis of a lifetime psychotic spectrum disorder, drug or alcohol dependence or abuse within the past three months and serious, unstable medical illness.
Patients were psychotropic medication-free for at least two weeks prior to the first infusion (five weeks for fluoxetine), with the exception of BD patients who were maintained on therapeutic levels of either lithium (0.6-1.2 mEq/L) or valproate (50-125 μg/mL).
Ketamine administration
Subjects received a single subanesthetic dose (0.5 mg/kg) of ketamine by intravenous infusion over 40 min. Ratings of depression, hypo/mania, psychotomimetic, and dissociative symptoms were measured using the HDRS (Hamilton, 1960 (Hamilton, , 1980 , Young Mania Rating Scale (YMRS) (Young et al., 1978) , Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) , and Clinician Administered Dissociative States Scale (CADSS) (Bremner et al., 1998) . Baseline and intra-infusion blood pressure and pulse were measured every 5 min for the first 40 min after starting the infusion with the subject reclining using a Philips Suresigns VS3 vital signs monitor. Psychiatric ratings were collected before and at 40, 80, 110, and 230 min after the start of infusion, and at various time points post-infusion.
Data analysis
Linear mixed models with restricted maximum likelihood estimation and compound symmetry covariance structures were used to examine changes in blood pressure and pulse over the course of the first 40 min and clinical ratings over the fisrst 230 min of the ketamine crossover studies. The phase-specific baseline was a covariate where a drug and time interaction was included in the model with their main effects. Bonferroni adjusted post hoc tests were used to examine drug differences at individual time points.
Using data from all ketamine treated subjects, Pearson correlations were calculated to examine the relationship between absolute changes in CADSS, BPRS total and positive symptoms, YMRS, and vital signs from baseline to 40 min and percent changes in HDRS at 230 min, Days 1 and 7 post-infusion. Significance was evaluated at p<0.05, two-tailed.
Results
All patients received a single ketamine infusion. Patients randomized to receive riluzole as an add-on treatment were excluded from analyses at Days 1 and 7.
The sample had moderate-to-severe depression in the current episode lasting an average of 55.7 (SD=97.2) months (Table 1 ). The sample was 85% Caucasian (n=92) with half females (n=54) and 21% (n=21) current smokers.
A linear mixed model showed a significant drug by time interaction indicating HDRS ratings were significantly lower on ketamine than placebo from 40 to 230 min (F=3.14, df=3,333, p=0.026) (Fig. 1A) . CADSS, YMRS, and BPRS positive symptoms were significantly increased on ketamine at 40 min only (CADSS: F=55.48, df=3, 209, p<0.001; YMRS: F=7.69, df=3, 332, p<0.001; BPRS Positive: F=27.38, df=3, 322, p<0.001) (Fig. 1B-D) . Similar models demonstrated significantly higher diastolic (F=264.95, df=1,640, p<0.001) and systolic (F=429.80, df=1,652, p<0.001) blood pressure and pulse (F=175.22, df=1,609, p<0 .001) on ketamine versus placebo from 5 to 40 min post-infusion (Fig. 2 ).
Correlations were significant between increased CADSS at 40 min and percent improvement in HDRS at 230 min (r= −0.35, p=0.007) and Day 7 (r= −0.41, p=0.01), but not Day 1 (r= −0.21, p=0.18 Fig. 3) . Changes in YMRS, BPRS total, or BPRS positive symptoms at 40 min were not significantly related to HDRS percent change at any point (Table 2) . Changes in systolic and diastolic blood pressure and pulse were not significantly related to depression changes.
Next, at 40 min, change in CADSS was positively correlated with change in BPRS positive symptoms (r=0.31, p=0.02) and total BPRS (r=0.34, p=0.008), but not with change in YMRS (r=0.22, p=0.11) ( Table 3 ). The largest magnitude correlation was between the BPRS positive symptom scale and YMRS (r=0.63, p<0.001). There were no significant correlations between vital sign changes and either CADSS, YMRS, BPRS total, or BPRS positive symptom changes. Changes in ketamine and norketamine levels were not significantly related to changes in depression or dissociation.
Discussion
In agreement with previous reports (Driesen et al., 2013; Gibbs, 1970; Krystal et al., 1994) , data from 108 depressed MDD or BD participants demonstrated that ketamine increased pulse, blood pressure, psychotomimetic and dissociative side effects. Dissociative side effects, but not psychotomimesis or sympathomimetic effects, correlated with change in depression on the day of infusion and seven days post-infusion. The present correlation suggests dissociative side effects as a clinical biomarker to predict ketamine's efficacy. Different underlying mechanisms may explain why dissociation predicts ketamine's antidepressant effect, but blood pressure, pulse, and psychotomimetic effects do not. Increases in blood pressure and psychotomimetic effects may be due to increases in dopamine. Microdialysis studies showed low-dose ketamine stimulated dopamine release in the conscious rat's prefrontal cortex (Moghaddam et al., 1997) . However, Adams et al. (2002) found that ketamine did not stimulate dopamine release in non-human primates. In humans, ketamine's effect on dopaminergic neuro-transmission is even more controversial (Aalto et al., 2005 (Aalto et al., , 2002 Breier et al., 1998; Smith et al., 1998; Kegeles et al., 2002; Vernaleken et al., 2013) . With regard to psychotomimetic effects, (Sos et al., 2013 ) BPRS subscales were not correlated with antidepressant response in depressed subjects. Similarly, we did not find correlations between positive symptoms or blood pressure and antidepressant response; these are presumably the behavioral and physiological correlates of a hyperdopaminergic state.
In contrast, dissociation may result from ketamine's enhancement of glutamate release. Based on the predominant theory of ketamine's antidepressant effect, i.e. the inhibition of GABAergic cortical interneurons leading to the depolarization of cortical projection (pyramidal) neurons, increased long-term potentiation-like synaptic glutamate release ("glutamate surge") and greater AMPA-to-NMDA postsynaptic receptor throughput (Dwyer and Duman, 2013; Maeng et al., 2008) , subjects with greater dissociation may also have greater presynaptic glutamate release, and vice versa, in response to subanesthetic dose ketamine . In addition, some evidence suggests psychotomimetic and dissociative symptoms following ketamine affect different areas of the brain. These data suggest possible avenues to pursue in mechanistic studies attempting to disentangle these factors.
Contrary to our results, a prior report found no correlation between maximum CADSS and HDRS response at any time following ketamine infusion (Valentine et al., 2011) . Also, (Sos et al., 2013) found that more intense psychotomimetic symptoms (as assessed by BPRS total) correlated with improved mood ratings on the MADRS 7 days post-ketamine infusion. These discrepant findings may be attributed to: (1.) small sample sizes, (2.) inclusion of bipolar patients, (3.) mandatory treatment-resistance, and/or (4.) different doses in some studies.
A limitation of this study is the combination of unipolar and bipolar diagnostic groups and the use of open-label and randomized, placebo-controlled studies. Another major caveat is the adequacy of blinding. Ketamine-induced psychotomimetic and vital sign alterations may have been so noticeable to subjects and researchers as to compromise blinding. Future investigations might employ an active control medication with hypertensive and/or dissociative effects but without antidepressant activity. Midazolam served as an active control in a trial supporting the efficacy of ketamine in treatment-resistant MDD (Murrough et al., 2013) . Nonetheless, improved blinding would not clarify the question of necessary or causal relationships between ketamine antidepressant and psychotomimetic/dissociative effects. Finally, although statistically significant, the CADSS change from baseline explained only a fraction of the variance in ketamine's antidepressant response. Thus, it remains unclear whether intra-infusion dissociation is necessary for ketamine's antidepressant response.
In conclusion, ketamine's dissociative adverse effects significantly correlated with antidepressant response, but only explained a fraction of the variance in response. Table 2 Pearson correlations of change in rating scales and levels with percent change in HDRS (from baseline). Abbreviations: BPRS=Brief Psychiatric Rating Scale; CADSS=Clinician-Administered Dissociative State Scale; HDRS=Hamilton Depression Rating Scale; YMRS=Young Mania Rating Scale. Table 3 Rating scale, vital sign, and drug level correlations (from baseline to 40-min post-infusion). 
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